Premaitha signs investment deal

Pioneering medical screening test company Premaitha Health has struck a £5m investment deal with one of the world’s largest scientific groups.

The Manchester-based firm, which has developed a pioneering non-invasive prenatal screening test called IONA, said its deal with Thermo Fisher Scientific will allow it to roll-out the product to more clinical laboratories across Europe and also boost further product development.

Thermo Fisher is the world leader in serving science, with revenues of $17bn and approximately 50,000 employees in 50 countries.

Dr Stephen Little, chief executive of Premaitha, said: “We have strengthened our relationship with Thermo Fisher as an investor in our business. This investment will enable us to expand our global reach, support our marketing and clinical and technical capabilities. It will also provide future product development opportunities in the rapidly growing non-invasive prenatal testing market.”

 

See article in full at BusinessDesk.com

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.